ASMB — ASSEMBLY BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1426800 ·
Last close
$22.96
Market Cap
$455.00M
52W High
$32.46
52W Low
$21.80
ADV30
197,140
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,213,000 | — | -11,370,000 | -9,079,000 | 235,508,000 | 31,120,000 | 36,898,000 |
| Dec 2025 | 42,469,000 | — | 19,799,000 | 22,090,000 | 257,590,000 | 58,450,000 | 50,839,000 |
| Sep 2025 | 10,789,000 | — | -10,883,000 | -9,196,000 | 239,997,000 | 22,534,000 | 57,302,000 |
| Jun 2025 | 9,626,000 | — | -11,093,000 | -10,198,000 | 80,780,000 | 24,006,000 | 62,680,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,093,000
Investing CF
$-113,468,000
Financing CF
$174,667,000
CapEx
$-24,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.73
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-832,047,000
Inventory
—
Receivables
$974,000
ST Investments
$189,656,000
EBIT TTM
$-12,118,000
Pretax Income TTM
$-6,122,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$71,097,000
EBITDA
$-13,425,000
Free Cash Flow
$-16,556,875
Enterprise Value
$140,784,272
Total Cash
$226,600,992
Total Debt
$2,491,000
Shares Out
19,817,250
Trailing EPS
$0.08
Book Value
$12.50
ROE
-5.7%
ROA
-5.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 72,303,000 | -12,118,000 | -6,122,000 | 257,590,000 | 50,839,000 | — | -41,093,000 |
| Dec 2024 | 28,520,000 | -45,420,000 | -40,177,000 | 119,168,000 | 85,809,000 | — | -51,117,000 |
| Dec 2023 | 7,163,000 | -64,646,000 | -61,228,000 | 136,823,000 | 95,726,000 | — | 22,743,000 |
| Dec 2022 | 0 | -94,114,000 | -93,092,000 | 101,794,000 | 19,130,000 | — | -84,463,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.10
Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $23.34 · call volume: 52 · put volume: 41Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NGNE | Neurogene Inc. | $459.84M | $29.10 | — |
| EOLS | Evolus, Inc. | $443.20M | $6.73 | — |
| STTK | Shattuck Labs, Inc. | $471.81M | $4.94 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $431.91M | $8.25 | — |
| EBS | Emergent BioSolutions Inc. | $429.28M | $8.32 | — |
News headlines (Yahoo Finance, 1h cache)
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
2026-06-08 17:03 · Yahoo
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
2026-06-05 19:03 · Yahoo
Assembly Biosciences Announces Upcoming Investor Conference Presentations
2026-05-28 20:05 · Yahoo
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2026-05-26 20:05 · Yahoo
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
2026-05-22 11:05 · Yahoo
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
2026-05-22 11:00 · Yahoo
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
2026-05-14 11:05 · Yahoo
These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts
2026-05-13 11:29 · Yahoo
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
2026-05-13 06:00 · Yahoo
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
2026-05-11 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.